Digest Network Come funziona
Network
/
Società
CE
Non verificato

CEL-SCI Corporation

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

58 comunicati stampa

Guarda tutti i comunicati
26/10/2026
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Oncologia
Eventi
Industria
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
15/09/2026
Biotecnologia
Farmaceutica
Salute
Oncologia
Eventi
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
17/08/2026
Mercato del lavoro
Industria
Mercato azionario
Scienza
Medicina - Varie
Igiene alimentare
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
CEL-SCI Reports Fiscal Third Quarter 2026 Results
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
04/08/2026
Analisi di mercato
Industria
Scienza
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
30/07/2026
Industria
Scienza
Libri/Editoria
Igiene alimentare
Medicina - Varie
Comunicazione
Biotecnologia
Farmaceutica
Salute
Oncologia
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
13/07/2026
Industria
Scienza
Medicina nucleare
Biotecnologia
Oncologia
Salute
Igiene alimentare
Medicina - Varie
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
24/06/2026
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
16/06/2026
Mercato azionario
Finanza
Sanità
Salute
Farmaceutica
Medicina - Varie
Oncologia
CEL-SCI Announces Closing of Offering
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
16/06/2026
Mercato del lavoro
Eventi
Industria
Scienza
Medicina - Varie
Igiene alimentare
Biotecnologia
Medicina nucleare
Farmaceutica
Salute
Oncologia
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
14/06/2026
Titoli e azioni
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
CEL-SCI Corporation Announces Pricing of Offering
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0